<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787371</url>
  </required_header>
  <id_info>
    <org_study_id>P04508</org_study_id>
    <secondary_id>JPC-04-356-20</secondary_id>
    <nct_id>NCT00787371</nct_id>
  </id_info>
  <brief_title>Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)</brief_title>
  <official_title>Study to Confirm Dose Response With PegIntron (SCH 54031) Monotherapy in Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of
      liver histology and inhibition of progression to liver cirrhosis and hepatocellular
      carcinoma (HCC). These effects are reported to be correlated with sustained ALT improvement.
      Therefore, the aim of this study is to determine if a low-dose (0.25, 0.5, or 1.0 mcg/kg SC
      QW) PegIntron monotherapy administered for 12 weeks will result in ALT normalization in
      Japanese patients with chronic hepatitis C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients who achieve normalization of ALT in each treatment group</measure>
    <time_frame>Measured at the end of 12 weeks of treatment or at discontinuation.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events, adverse reactions, laboratory test result (hematology, blood biochemistry and thyroid function test)</measure>
    <time_frame>Measured between when the patient signs the informed consent form and the end of post-treatment follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>0.25 Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron 0.25 mcg/kg SC QW for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron 0.5 mcg/kg SC QW for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron 1.0 mcg/kg SC QW for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment (no placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b)</intervention_name>
    <description>PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks</description>
    <arm_group_label>0.25 Dose Group</arm_group_label>
    <other_name>PegIntron, peginterferon alfa-2b, SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b)</intervention_name>
    <description>PegIntron 0.5 mcg/kg SC QW for 12 weeks</description>
    <arm_group_label>0.5 Dose Group</arm_group_label>
    <other_name>PegIntron, peginterferon alfa-2b, SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b)</intervention_name>
    <description>PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks</description>
    <arm_group_label>1.0 Dose Group</arm_group_label>
    <other_name>PegIntron, peginterferon alfa-2b, SCH 54031</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with chronic hepatitis C patients (CHC) who met all of the following criteria:

          -  At least 20 years of age and willing to sign an informed consent

          -  Patients who can practice contraception

          -  Patients who are classified either as relapsers or non-responders.

          -  Weight between 45 and 100 kg

          -  Patients willing to be hospitalized for 3 days after the start of treatment

          -  Patients with positive HCV-RNA

          -  Serum ALT level: Over 60 IU/L, equal to or less than 150 IU/L

          -  Neutrophil count: equal to or more than 1,200 /mm^3

          -  Platelet countï¼šequal to or more than 100,000/mm^3

        Exclusion Criteria:

          -  Patients with conditions which would interfere with the evaluation of therapeutic
             efficacy of the study drug and patients for whom assurance of safety is a concern
             were excluded from the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 9, 2015</lastchanged_date>
  <firstreceived_date>November 6, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alanine transaminase</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
